Company intelligence / Profile preview
Trefoil Therapeutics
San Diego, California, United Statestrefoiltherapeutics.com ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Phase 2
01
Overview
Trefoil Therapeutics’ lead candidate TTHX1114, an engineered variant of FGF1, has shown in Phase 2 clinical trials to improve the rate of visual recovery after Descemet Stripping Only (DSO) surgery in patients with corneal endothelial dystrophies. The company also completed a Phase 1 safety study for a topical formulation targeting epithelial disorders in April 2023. Both formulations aim to stimulate regeneration and protection of corneal cells, addressing significant unmet needs in ophthalmology.
- Therapeutic areas
- Ophthalmology
- Modalities
- Engineered proteins (specifically engineered FGF1/eFGF1)Biologics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Technology licensed from Florida State University; no major pharma partnerships disclosed.
Beyond the preview
Go deeper on Trefoil Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trefoil Therapeutics.